These findings could have implications for traditional checkpoint inhibition therapy (anti-CTLA-4 or anti-PD-1), in that the expression of HLA-G could serve as an alternate route for immune evasion in BRAF mutated GBM. This evidence concerns the gene HLA-G and glioblastoma.